A proposed new strategy of immunotherapy for Alzheimer's disease

Medical Hypotheses

Volumn 49, Issue 4, 1997, Pages 319-326

  Gasiorowski K ^a   Leszek, J ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; AGING; ALZHEIMER DISEASE; BRAIN TISSUE; HUMAN; IMMUNOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENILE PLAQUE;

EID: 0030773299     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90198-5     Document Type: Article

References (63)

1. Cacabelos R. Alzheimer's disease: etiopathogenetic factors. Neurogerontol Neurogeriat 1995; 1: 299-328.
2. Cacabelos R, Hofman A, Mullan M et al. Alzheimer's disease: scientific progress for future trends. Drug News Perspect 1993; 6: 242-244.
3. Cacabelos R. Alzheimer's disease: news and prospects. Drug News Perspect 1992; 5: 501-506.
4. Amaducci L, Falcini M, Lippi A. Descriptive epidemiology and risk factors for Alzheimer's disease. Acta Neurol Scand Suppl 1992; 139: 21-25.
5. Cacabelos R. Genetic markers in neuropsychiatric disorders: genetic mapping and diagnostic and therapeutic perspectives (II). Med Clin 1993; 100: 28-36.
6. Samuel W, Terry R D, De Teresa R et al. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch Neurol 1994; 51: 772-778.
7. McGeer P L, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992; 42: 447-449.
8. Leszek J, Dobránska I, Ga̧siorowski K. Alzheimer's disease - immunological aspects. Acta Neurobiol Exp 1993; 53: 351-355.
9. Rogers J. Inflammation as a pathogenic mechanism in Alzheimer's disease. Drug Res 1995; 45: 439-442.
10. Wucherpfennig K W. Autoimmunity in the Central Nervous System: mechanisms of antigen presentation and recognition. Short analytical review. Clin Immunol Immunopathol 1994; 72: 293-306.
11. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol 1989; 77: 569-575.
12. Wegiel J, Wisniewski H M. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol (Berlin) 1990; 81: 116-124.
13. Wiśniewski H M, Wȩgiel J, Wang K-C et al. Ultrastructural studies of the cells forming amyloid in the vessel wall in Alzheimer's disease. Acta Neuropathol (Berlin) 1992; 84: 117-127.
14. Shaffer L M, Shein D S, Brannaman C A et al. Processing of neuronally-generated β-APP by macrophages and microglia. J Neuropathol Exp Neurol 1993; 52: 296-312.
15. Sebire G, Emilie D, Walton C et al. In vitro production of IL-6, Il-1 beta and tumor necrosis factor-alpha by human embryonic microglial and neural cells. J Immunol 1993; 150: 1517-1523.
16. Lee S C, Liu W, Dickson D W et al. Cytokine production by human fetal microglia and astrocytes: differential induction by lipopolysaccharide and Il-1 beta. J Immunol 1993; 150: 2659-2667.
17. Passinetti G M, Johnson S A, Rozovsky I et al. Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp Neurol 1992; 118: 117-125.
18. McRae A, Dahlström A, Polinsky R et al. Cerebrospinal fluid microglial antibodies: potential diagnostic markers for immune mechanisms in Alzheimer's disease. Behav Brain Res 1993; 57: 225-234.
19. Rogers J, Luber-Narod J, Styren S et al. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Ageing 1988; 9: 339-349.
20. Itagaki S, McGeer P L, Akiyama H. Presence of T-cytotoxic suppressor and leukocyte common antigen positive cells in Alzheimer disease brain tissue. Neurosci Lett 1988; 31: 259-264.
21. Hartwig M. Immune ageing and Alzheimer's disease. Neuro-Report 1995; 6: 1274-1276.
22. van Noort J M. Multiple sclerosis: an altered immune response or an altered stress response? Review. J Mol Med 1996; 74: 285-296.
23. Frei K, Lins H, Schwerdel C et al. Antigen presentation in the Central Nervous System: the inhibitory effect of 11-10 on MHC class II expression and production of cytokines depends on the inducing signals and the type of cell analyzed. J Immunol 1994; 152: 2720-2728.
24. Otten U, Gadient R A. Neurotrophins and cytokines - intermediaries between the immune and nervous systems. Int J Dev Neurosci 1995; 13: 147-150.
25. Singh V K. Studies of neuroimmune markers in Alzheimer's disease. Mol Neurobiol 1994; 9: 73-81.
26. Araga S, Kagimoto H. Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol Scand 1991; 84: 259-263.
27. Hu G R, Walls R S, Creasey H et al. Peripheral blood lymphocyte subset distribution and function in patients with Alzheimer's disease and other dementias. Austr NZ J Med 1995; 25: 212-217.
28. Westermann J, Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 1990; 11: 406-410.
29. Mrak R E, Sheng J G, Griffin W S T. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol 1995; 26: 816-823.
30. Griffin W S T, Sheng J G, Gentleman S M et al. Microglial interleukin-1α expression in human head injury: correlations with neuronal and neuritic β-amyloid precursor protein expression. Neurosci Lett 1994; 176: 133-136.
31. Mrak R E, Sheng J G, Griffin W S T. Correlation of astrocytic S100β expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55: 273-279.
32. Griffin W S T, Sheng J G, Roberts G W et al. Interleukin-1 expression of different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54: 276-281.
33. Sheng J G, Mrak R E, Rovnaghi C R et al. Human brain S100β and S100β mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Neurol Ageing 1996; 17: 359-363.
34. Cacabelos R The ageing process and theories of ageing: implications for neurogerontology. Neurogerontol Neurogeriat 1995; 1: 5-20.
35. Eren R, Zharhary D, Abel L et al. Age-related changes in the capacity of bone marrow cells to differentiate in thymic organ cultures. Cell Immunol 1988; 112: 449-455.
36. Globerson A. T lymphocytes and ageing: mini review. Int Arch Allergy Appl Immunol 1995; 107: 491-497.
37. Globerson A. Thymocyte progenitors in ageing. Immunol Lett 1994; 40: 219-224.
38. Cserr H S, Knopf P M. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 1992; 13: 507-511.
39. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992; 12: 198-210.
40. de Waal M, Abrams R J, Bennett B et al. Interleukin 10 (Il-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of Il-10 produced by monocytes. J Exp Med 1991; 174: 1209-1213.
41. Constam D, Phillip J, Molipiero U V et al. Differential expression of transforming growth factor-β1, -β2 and -β3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992; 148: 1404-1414.
42. Wostyn P. Intracranial pressure and Alzheimer's disease: a hypothesis. Med Hypothese 1994; 43: 219-222.
43. Nijhuis E, Hinloopen B, Van Duijn C et al. Decreased sensitivity to dexamethasone in lymphocytes from patients with Alzheimer's disease. Clin Immunol Immunopathol 1994; 73: 45-52.
44. Aisen P S. Anti-inflammatory therapy for Alzheimer's disease. Dementia 1995; 9: 173-182.
45. Mastrangelo M J, Berd D, Maguire H. The immunoaugmentic effects of cancer chemotherapeutic agents. Semin Oncol 1986; 13: 186-194.
46. Turowski R C, Triozzi P L. Application of chemical immunomodulators to the treatment of cancer and AIDS. Cancer Invest 1994; 12: 620-643.
47. Leszek J, Ga̧siorowski K. Therapeutic efficacy of Cyclophosphamide in Alzheimer's disease. Alzheimer's Res 1996; 2: 43-46.
48. Alvarez X A, Zas R, Lagares R et al. Neuroimmunomodulatory and neurotrophic activity of anapses: studies with laboratory animals. Ann Psychiatry 1995; 5: 267-280.
49. Leszek J, Ga̧siorowski K, Tolpa S et al. Peat extract (PTT) treatment of Alzheimer's disease: preliminary study. Eur J Psychiatry 1993; 7: 69-72.
50. Rogers J, Kirby L C, Hempelman S R et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
51. Breitner J C S The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996; 47: 401-411.
52. Schnabel J. New Alzheimer's therapy suggested. Science 1993; 260: 1719-1720.
53. Soares J C, Gershon S. Advances in the pharmacotherapy of Alzheimer's disease. Eur Arch Psych Clin Neurosci 1994; 244: 261-271.
54. Aisen P S, Davis K L. Inflammatory mechanisms in Alzheimer's disease: implication for therapy. Am J Psychiatry 1994; 151: 1105-1113.
55. Jenkinson M L, Bliss M R, Brain A T et al. Rheumatoid arthritis and senile dementia of Alzheimer's type. Br J Rheumatol 1989; 28: 86-88.
56. Beard C M, Krokman E, Kurland L T. Rheumatoid arthritis and susceptibility to Alzheimer's disease. Lancet 1991; 337: 1426.
57. Breitner J C S, Gau B A, Welsh K A et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin study. Neurology 1994; 44: 227-232.
58. Broe G A, Henderson A S, Creasey H. A case-control study of Alzheimer's disease in Australia. Neurology 1990; 40: 1698-1707.
59. Li G, Shen Y C, Li Y T et al. A case-control study of Alzheimer's disease in China. Neurology 1992; 42: 1481-1488.
60. Andersen K, Launer L J, Ott A et al. Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 1995; 45: 1441-1445.
61. Brooks P M, Day R O. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991; 324: 1716-1725.
62. Madison DV, Malenka RC, Nicoll R A. Mechanisms of underlying long-term potentation of synaptic transmission. Annu Rev Neurosci 1991; 14: 379-397.
63. Smeyne R J, Vendrell M, Hayward M et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature 1993; 363: 166-169.